DM
Drugs Made In America Acquisition Corp. Rights (DMAAR)
NASDAQ·Financial Services·Shell Companies
$0.16
+0.06%
Mkt Cap $2.30M
Analyst Ratings
No recent rating data.
Price Target (28 analysts)
$230.00
Range $156.00 – $270.00
Implied Upside
+143650.0%
Consensus $230.00 vs current $0.16